Annual EBITDA:
$21.48B+$1.34B(+6.65%)Summary
- As of today, NVS annual EBITDA is $21.48 billion, with the most recent change of +$1.34 billion (+6.65%) on December 31, 2024.
- During the last 3 years, NVS annual EBITDA has risen by +$4.45 billion (+26.15%).
- NVS annual EBITDA is now at all-time high.
Performance
NVS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
$5.45B-$479.73M(-8.09%)Summary
- As of today, NVS quarterly EBITDA is $5.45 billion, with the most recent change of -$479.73 million (-8.09%) on September 29, 2025.
- Over the past year, NVS quarterly EBITDA has dropped by -$579.98 million (-9.62%).
- NVS quarterly EBITDA is now -16.33% below its all-time high of $6.52 billion, reached on September 30, 2023.
Performance
NVS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$22.49B-$579.98M(-2.51%)Summary
- As of today, NVS TTM EBITDA is $22.49 billion, with the most recent change of -$579.98 million (-2.51%) on September 29, 2025.
- Over the past year, NVS TTM EBITDA has increased by +$2.06 billion (+10.10%).
- NVS TTM EBITDA is now -2.51% below its all-time high of $23.07 billion, reached on June 30, 2025.
Performance
NVS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
NVS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +6.7% | -9.6% | +10.1% |
| 3Y3 Years | +26.1% | +34.5% | +26.0% |
| 5Y5 Years | +35.0% | +16.0% | +34.8% |
NVS EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +26.1% | -16.3% | +34.5% | -2.5% | +26.0% |
| 5Y | 5-Year | at high | +35.0% | -16.3% | +38.9% | -2.5% | +34.8% |
| All-Time | All-Time | at high | +417.3% | -16.3% | +149.6% | -2.5% | +1598.2% |
NVS EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2025 | - | $5.45B(-8.1%) | $22.49B(-2.5%) |
| Jun 2025 | - | $5.93B(+3.5%) | $23.07B(+3.8%) |
| Mar 2025 | - | $5.73B(+6.7%) | $22.23B(+3.7%) |
| Dec 2024 | $21.48B(+6.7%) | $5.37B(-11.0%) | $21.44B(+5.0%) |
| Sep 2024 | - | $6.03B(+18.5%) | $20.42B(-2.3%) |
| Jun 2024 | - | $5.09B(+3.0%) | $20.91B(+3.4%) |
| Mar 2024 | - | $4.94B(+13.4%) | $20.22B(+1.3%) |
| Dec 2023 | $20.14B(+18.0%) | $4.36B(-33.1%) | $19.97B(-5.0%) |
| Sep 2023 | - | $6.52B(+47.9%) | $21.02B(+13.3%) |
| Jun 2023 | - | $4.40B(-6.0%) | $18.56B(-3.4%) |
| Mar 2023 | - | $4.69B(-13.3%) | $19.21B(+1.8%) |
| Dec 2022 | $17.07B(+0.2%) | $5.41B(+33.4%) | $18.87B(+5.7%) |
| Sep 2022 | - | $4.05B(-19.8%) | $17.85B(-3.6%) |
| Jun 2022 | - | $5.05B(+16.2%) | $18.51B(+3.0%) |
| Mar 2022 | - | $4.35B(-0.8%) | $17.97B(-0.5%) |
| Dec 2021 | $17.03B(+6.9%) | $4.39B(-6.9%) | $18.07B(+2.6%) |
| Sep 2021 | - | $4.71B(+4.4%) | $17.61B(+0.1%) |
| Jun 2021 | - | $4.52B(+1.5%) | $17.59B(+4.0%) |
| Mar 2021 | - | $4.45B(+13.4%) | $16.92B(-0.0%) |
| Dec 2020 | $15.93B(+0.1%) | $3.92B(-16.5%) | $16.93B(+1.5%) |
| Sep 2020 | - | $4.70B(+22.2%) | $16.68B(+3.6%) |
| Jun 2020 | - | $3.85B(-13.7%) | $16.11B(+0.5%) |
| Mar 2020 | - | $4.46B(+21.2%) | $16.03B(+4.8%) |
| Dec 2019 | $15.92B(+13.3%) | $3.68B(-10.9%) | $15.30B(+3.0%) |
| Sep 2019 | - | $4.13B(+9.3%) | $14.85B(+3.7%) |
| Jun 2019 | - | $3.77B(+1.2%) | $14.33B(+2.8%) |
| Mar 2019 | - | $3.73B(+15.6%) | $13.94B(+3.7%) |
| Dec 2018 | $14.05B(-2.4%) | $3.23B(-10.4%) | $13.44B(-4.5%) |
| Sep 2018 | - | $3.60B(+6.2%) | $14.07B(-2.3%) |
| Jun 2018 | - | $3.39B(+4.9%) | $14.40B(-2.3%) |
| Mar 2018 | - | $3.23B(-16.2%) | $14.74B(-3.8%) |
| Dec 2017 | $14.39B(+5.2%) | $3.86B(-1.9%) | $15.32B(+2.2%) |
| Sep 2017 | - | $3.93B(+5.6%) | $14.99B(+0.5%) |
| Jun 2017 | - | $3.72B(-2.4%) | $14.92B(-0.9%) |
| Mar 2017 | - | $3.81B(+8.2%) | $15.05B(+1.3%) |
| Dec 2016 | $13.69B(-9.8%) | $3.53B(-8.6%) | $14.86B(+2.1%) |
| Sep 2016 | - | $3.86B(+0.1%) | $14.56B(+0.4%) |
| Jun 2016 | - | $3.85B(+6.5%) | $14.50B(-1.6%) |
| Mar 2016 | - | $3.62B(+12.3%) | $14.74B(-3.5%) |
| Dec 2015 | $15.18B(-11.1%) | $3.22B(-15.2%) | $15.27B(-3.2%) |
| Sep 2015 | - | $3.80B(-7.2%) | $15.78B(-2.9%) |
| Jun 2015 | - | $4.09B(-1.4%) | $16.25B(-4.3%) |
| Mar 2015 | - | $4.16B(+11.5%) | $16.99B(-0.2%) |
| Dec 2014 | $17.07B(+2.5%) | $3.73B(-12.8%) | $17.02B(-0.3%) |
| Sep 2014 | - | $4.27B(-11.6%) | $17.07B(+1.7%) |
| Jun 2014 | - | $4.83B(+15.4%) | $16.79B(+3.4%) |
| Mar 2014 | - | $4.19B(+10.8%) | $16.23B(+2.9%) |
| Dec 2013 | $16.65B(-0.8%) | $3.78B(-5.2%) | $15.78B(+2.9%) |
| Sep 2013 | - | $3.99B(-6.8%) | $15.33B(+2.9%) |
| Jun 2013 | - | $4.28B(+14.8%) | $14.90B(+4.2%) |
| Mar 2013 | - | $3.73B(+11.8%) | $14.30B(+4.0%) |
| Dec 2012 | $16.78B(+17.8%) | $3.34B(-6.1%) | $13.75B(+9.8%) |
| Sep 2012 | - | $3.55B(-3.5%) | $12.52B(-3.9%) |
| Jun 2012 | - | $3.68B(+15.9%) | $13.03B(-3.0%) |
| Mar 2012 | - | $3.18B(+50.5%) | $13.44B(-7.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2011 | $14.25B(+21.2%) | $2.11B(-48.1%) | $14.55B(-7.1%) |
| Sep 2011 | - | $4.07B(-0.5%) | $15.66B(+2.0%) |
| Jun 2011 | - | $4.09B(-4.8%) | $15.35B(+6.5%) |
| Mar 2011 | - | $4.29B(+33.3%) | $14.41B(+2.6%) |
| Dec 2010 | $11.76B(+5.3%) | $3.22B(-14.3%) | $14.05B(-3.7%) |
| Sep 2010 | - | $3.76B(+19.3%) | $14.59B(+3.2%) |
| Jun 2010 | - | $3.15B(-19.7%) | $14.13B(+1.5%) |
| Mar 2010 | - | $3.92B(+4.3%) | $13.93B(+9.3%) |
| Dec 2009 | $11.16B(-8.0%) | $3.76B(+14.0%) | $12.74B(+13.3%) |
| Sep 2009 | - | $3.30B(+12.1%) | $11.25B(+2.6%) |
| Jun 2009 | - | $2.94B(+7.5%) | $10.96B(-0.2%) |
| Mar 2009 | - | $2.74B(+20.6%) | $10.98B(-0.1%) |
| Dec 2008 | $12.13B(+25.1%) | $2.27B(-24.8%) | $10.99B(+10.7%) |
| Sep 2008 | - | $3.02B(+1.9%) | $9.93B(+1.8%) |
| Jun 2008 | - | $2.96B(+7.6%) | $9.76B(+4.8%) |
| Mar 2008 | - | $2.75B(+127.6%) | $9.31B(-0.3%) |
| Dec 2007 | $9.70B(+3.8%) | $1.21B(-57.4%) | $9.34B(-7.3%) |
| Sep 2007 | - | $2.84B(+13.2%) | $10.07B(+3.2%) |
| Jun 2007 | - | $2.51B(-9.8%) | $9.76B(+1.4%) |
| Mar 2007 | - | $2.78B(+43.3%) | $9.63B(+3.6%) |
| Dec 2006 | $9.34B(+14.2%) | $1.94B(-23.3%) | $9.30B(+0.6%) |
| Sep 2006 | - | $2.53B(+6.6%) | $9.24B(+0.8%) |
| Jun 2006 | - | $2.37B(-3.0%) | $9.17B(+3.2%) |
| Mar 2006 | - | $2.45B(+29.8%) | $8.88B(+8.5%) |
| Dec 2005 | $8.18B(+12.2%) | $1.89B(-23.2%) | $8.19B(+1.1%) |
| Sep 2005 | - | $2.46B(+17.5%) | $8.10B(+6.2%) |
| Jun 2005 | - | $2.09B(+19.0%) | $7.62B(-0.3%) |
| Mar 2005 | - | $1.76B(-2.2%) | $7.64B(-1.6%) |
| Dec 2004 | $7.30B(+2.5%) | $1.80B(-9.4%) | $7.77B(-2.2%) |
| Sep 2004 | - | $1.98B(-6.1%) | $7.95B(+1.9%) |
| Jun 2004 | - | $2.11B(+12.0%) | $7.80B(+3.8%) |
| Mar 2004 | - | $1.88B(-4.5%) | $7.51B(+1.9%) |
| Dec 2003 | $7.12B(+11.9%) | $1.97B(+7.6%) | $7.37B(+5.8%) |
| Sep 2003 | - | $1.83B(+0.3%) | $6.97B(+5.2%) |
| Jun 2003 | - | $1.83B(+4.6%) | $6.62B(+6.1%) |
| Mar 2003 | - | $1.75B(+11.4%) | $6.24B(-33.3%) |
| Dec 2002 | $6.36B(+19.0%) | $1.57B(+5.4%) | $9.35B(+723.1%) |
| Sep 2002 | - | $1.49B(+3.1%) | -$1.50B(-158.0%) |
| Jun 2002 | - | $1.44B(-70.3%) | $2.59B(+22.2%) |
| Mar 2002 | - | $4.86B(+152.3%) | $2.12B(+24.6%) |
| Dec 2001 | $5.35B(-4.8%) | -$9.29B(-266.6%) | $1.70B(>+9900.0%) |
| Sep 2001 | - | $5.58B(+474.3%) | $0.00(+100.0%) |
| Jun 2001 | - | $971.00M(-78.1%) | -$695.00M(-4.4%) |
| Mar 2001 | - | $4.44B(+140.4%) | -$666.00M(-212.7%) |
| Dec 2000 | $5.62B(-6.4%) | -$10.99B(-325.1%) | $591.00M(-94.9%) |
| Sep 2000 | - | $4.88B(+388.1%) | $11.58B(+72.9%) |
| Jun 2000 | - | $1.00B(-82.4%) | $6.70B(+17.6%) |
| Mar 2000 | - | $5.70B | $5.70B |
| Dec 1999 | $6.00B(-0.6%) | - | - |
| Dec 1998 | $6.03B(+8.4%) | - | - |
| Dec 1997 | $5.57B(-6.3%) | - | - |
| Dec 1996 | $5.94B(-4.8%) | - | - |
| Dec 1995 | $6.24B(+22.5%) | - | - |
| Dec 1994 | $5.10B(+22.7%) | - | - |
| Dec 1993 | $4.15B | - | - |
FAQ
- What is Novartis AG annual EBITDA?
- What is the all-time high annual EBITDA for Novartis AG?
- What is Novartis AG annual EBITDA year-on-year change?
- What is Novartis AG quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Novartis AG?
- What is Novartis AG quarterly EBITDA year-on-year change?
- What is Novartis AG TTM EBITDA?
- What is the all-time high TTM EBITDA for Novartis AG?
- What is Novartis AG TTM EBITDA year-on-year change?
What is Novartis AG annual EBITDA?
The current annual EBITDA of NVS is $21.48B
What is the all-time high annual EBITDA for Novartis AG?
Novartis AG all-time high annual EBITDA is $21.48B
What is Novartis AG annual EBITDA year-on-year change?
Over the past year, NVS annual EBITDA has changed by +$1.34B (+6.65%)
What is Novartis AG quarterly EBITDA?
The current quarterly EBITDA of NVS is $5.45B
What is the all-time high quarterly EBITDA for Novartis AG?
Novartis AG all-time high quarterly EBITDA is $6.52B
What is Novartis AG quarterly EBITDA year-on-year change?
Over the past year, NVS quarterly EBITDA has changed by -$579.98M (-9.62%)
What is Novartis AG TTM EBITDA?
The current TTM EBITDA of NVS is $22.49B
What is the all-time high TTM EBITDA for Novartis AG?
Novartis AG all-time high TTM EBITDA is $23.07B
What is Novartis AG TTM EBITDA year-on-year change?
Over the past year, NVS TTM EBITDA has changed by +$2.06B (+10.10%)